- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Federal Negotiations for Medicare Part D Drug Pricing?
The President's budget proposal for 2016 seeks to gain the ability to negotiate drug prices under Medicare Part D, which will definitely face resistance from the Republican-controlled Congress.
The Obama administration said on Monday it would seek authority to negotiate pricing for high-cost drugs under the federal government's Medicare Part D program, which offers private insurance drug coverage for senior citizens and the disabled.
Barack Obama's new $3.99 trillion budget for fiscal-year 2016 proposes allowing the US Secretary for HHS to negotiate prices for biotechnology treatments and other high-cost drugs in Part D "to ensure access to and affordability of these treatments."
The move to add negotiating authority on drug prices is likely to draw fierce resistance in the Republican-controlled Congress. Lawmakers prohibited Medicare from negotiating prices directly with drug companies when it created the voluntary Part D program under former President George W. Bush in 2003.
Link to the complete Reuters article: http://reut.rs/1yw1pgs
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
